Genomic Health
PreludeDx DCIS Breast Cancer Test Helps Determine Radiation Therapy Benefits, Reduce Overtreatment
Premium
The test uses prognostic markers to group women based on their risk of 10-year recurrence of ductal carcinoma in situ.
Biocartis to Invest in IVD Partnerships Following Termination of Genomic Health Deal
The firm will partner with startup GeneproDx on thyroid cancer diagnostic development, while a separate agreement with Endpoint Health will entail CDx development for critical illness.
Biocartis, Exact Sciences Terminate Oncotype DX Agreement
The firms had planned to develop the assay on Biocartis' Idylla platform, which would have allowed customers to perform the assay locally in their own lab facilities.
Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.
Exact Sciences Q2 Revenues Up 35 Percent, Buoyed by COVID-19 Testing Sales
The firm reported that revenues from screening products fell 34 percent year over year, but that it took in $34.6 million in revenues from COVID-19 testing.